ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the safety and efficacy of topical application of recombinant bovine basic fibroblast growth factor (rbFGF) on the healing of chronic cutaneous wounds.</p><p><b>METHODS</b>Twenty-eight patients with thirty-three chronic cutaneous wounds resulting from trauma, diabetes mellitus, pressure sore and radiation injuries were enrolled in this prospective, open-label crossover trial. Prior to treatment with rbFGF, all wounds failed to heal with conventional therapies within 4 weeks. All wounds were locally treated with rbFGF at a dose of 150 AU/cm(2). Healing time and the quality of wounds were used to evaluate the efficacy of the treatment.</p><p><b>RESULTS</b>Healing of all chronic wounds was expedited. During the study, eighteen wounds completely healed within 2 weeks, four healed within 3 weeks, and another eight completely healed within 4 weeks. Only three wounds failed to heal within 4 weeks, but healed at 30, 40 and 42 days after treatment with rbFGF. Thus, compared with conventional therapies, the effective rate of rbFGF treatment within 4 weeks was 90.9%. Histological assessment showed more abundant capillary sprouts or tubes and that fibroblasts were differentiated in wounds treated with rbFGF. No adverse side effects related to basic fibroblast growth factor were observed.</p><p><b>CONCLUSIONS</b>Our results indicate that rbFGF could be used to accelerate healing in chronic wounds. It is our belief that this may be a more effective method of chronic wound management.</p>
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Administration, Topical , Chronic Disease , Fibroblast Growth Factor 2 , Therapeutic Uses , Recombinant Proteins , Therapeutic Uses , Skin , Wounds and Injuries , Skin Ulcer , Drug Therapy , Wound HealingABSTRACT
Objective To investigate the effect of H.pylori eradication on intestinal metaplasia of gastric mucosa. Methods A total of 398 patients with H.pylori positive determined by rapid urease test (RUT) and confirmed in histology were randomized into two groups: the treatment group and the control group. The patients of treatment group (201 patients) were received H.pylori eradication therapy, and the patients of control group (197 patients) were given placebo. The intestinal metaplasia of gastric mucosa was determined at gastric biopsy specimens taken from both the antrum and corpus before and after five years of treatment. Results Five years later, there are 151 H.pylori negative patients in treatment group, and 161 H.pylori positive patients in control group. After eradication therapy, the detectable rates of active gastritis in H.pylori negative patients of treatment group were significantly decreased compared with those in H.pylori positive patients of control group ( P
ABSTRACT
Objective To investigate the morbidity and Helicobacter pylori (H.pylori) reinfection status within 5 years after eradication. Methods One thousand and six adults aged between 35 to 37 were selected from general population in the high incidence region of gastric cancer. Among them, 552 individuals were confirmed to be H.pylori positive by both CLO test and Warthin Starry Stain histology. All the H.pylori positive individuals were randomly divided into two groups: treatment group receiving OAC triple therapy for one week and placebo group as controls. One month after cessation of treatment, the H.pylori eradication rate was 88.9%, while in the control group the H.pylori infection rate still remained 96.4% by 13 C UBT. These subjects were endoscopically followed up at the end of first and fifth years, respectively. H.pylori infected status was studied by histology and CLO test. Results 1. At 1 and 5 years after eradication, the response rates of subjects were 89.13% and 83.11%, respectively. 2. The morbidity rates of peptic ulcer, before treatment, were 9.87% and 7.61% in the treatment group and control group, respectively. At the 1st year, the morbidity rates were 3.70% and 12.85% in the two groups ( P